RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells.

PURPOSE: Phase II trial to study the effectiveness of donor peripheral stem cell transplantation in treating patients who have hematologic cancer.

Condition	Treatment or Intervention	Phase
Langerhans cell histiocytosis childhood Hodgkin's lymphoma childhood non-Hodgkin's lymphoma hematopoietic and lymphoid cancer	Procedure: biological response modifier therapy  Procedure: bone marrow ablation with stem cell support  Procedure: peripheral blood stem cell transplantation	Phase II

Further Study Details: 

OBJECTIVES:

• Determine the efficacy and safety of allogeneic peripheral blood stem cell transplantation in achieving engraftment in patients with hematologic malignancy.
• Determine the hematopoietic recovery, incidence of chemoradiotherapeutic toxicity, relapse, graft-versus-host disease, and survival of patients treated with this regimen.

OUTLINE: Patients receive a preparative chemoradiotherapeutic regimen and graft-versus-host disease prophylaxis prior to transplantation. Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.

Patients are followed every 1-2 weeks for 6 months and at 9, 12, 24, and 36 months.

PROJECTED ACCRUAL: A total of 62 patients will be accrued for this study within 4 years.

Ages Eligible for Study:  up to  65 Years,  Genders Eligible for Study:  Both

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of one of the following:
• Chronic myelogenous leukemia
• Philadelphia chromosome-positive OR
• Molecular evidence of bcr/abl gene rearrangement
• Acute myeloid leukemia, acute lymphocytic leukemia, lymphoma, histiocytoses, myelodysplasia, juvenile chronic myelomonocytic leukemia, aplastic anemia, paroxysmal nocturnal hemoglobinuria, or Fanconi's anemia
• Confirmed by cytochemistry, immunophenotyping, and/or chromosomal abnormalities
• Multiple myeloma
• Hereditary immunodeficiency disorders
• Confirmed by immunologic determination
• Sickle cell anemia or beta-thalassemia
• Confirmed by hemoglobin electrophoresis
• Storage disorders (e.g., Gaucher's disease, Hurler's disease, or metachromatic leukodystrophy)
• Confirmed by metabolic testing
• Other non-malignant conditions
• Eligible for allogeneic peripheral blood stem cell or bone marrow transplantation

PATIENT CHARACTERISTICS: Age:

• 65 and under

Performance status:

• Not specified

Life expectancy:

• Not specified

Hematopoietic:

• Not specified

Hepatic:

• Not specified

Renal:

• Not specified

PRIOR CONCURRENT THERAPY: Biologic therapy

• Not specified

Chemotherapy

• Not specified

Endocrine therapy

• Not specified

Radiotherapy

• Not specified

Surgery

• Not specified

New York
      Herbert Irving Comprehensive Cancer Center at Columbia University, New York,  New York,  10032,  United States; Recruiting

Study chairs or principal investigators

David G. Savage, MD,  Study Chair,  Herbert Irving Comprehensive Cancer Center   

Study ID Numbers:  CDR0000068388; CPMC-IRB-7651; CPMC-CAMP-016; NCI-G00-1891; NCT00008216
Record last reviewed:  November 2001
Last Updated:  February 4, 2005
Record first received:  January 6, 2001
ClinicalTrials.gov Identifier:  NCT00008216
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08